newsfilter
← Latest News
Business Wire·

Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)

Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera's Treatment on MRD (TOMR) approach as the new standard of care in MIBC, enabling